A
Anders G. Olsson
Researcher at Linköping University
Publications - 258
Citations - 33138
Anders G. Olsson is an academic researcher from Linköping University. The author has contributed to research in topics: Atorvastatin & Cholesterol. The author has an hindex of 65, co-authored 257 publications receiving 31983 citations. Previous affiliations of Anders G. Olsson include Veterans Health Administration & Park University.
Papers
More filters
Journal Article
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)
Anders G. Olsson,Jjv McMurray,Gudmundur Thorgeirsson,C Spaulding,J Slattery,Kalevi Pyörälä,Ole Faergeman,RA Wright,Kåre Berg,Lars Wilhelmsen,Terje R. Pedersen,Tatu A. Miettinen,Harvey D. White,John Kjekshus,Michael Gnant +14 more
Journal ArticleDOI
Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial.
Gregory G. Schwartz,Anders G. Olsson,Michael D. Ezekowitz,Peter Ganz,Michael F. Oliver,David D. Waters,Andreas M. Zeiher,Bernard R. Chaitman,S. Leslie,Theresa Stern +9 more
TL;DR: Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes and the MIRACL study are studied.
Journal ArticleDOI
Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome
Gregory G. Schwartz,Anders G. Olsson,Markus Abt,Christie M. Ballantyne,Philip J. Barter,Jochen Brumm,Bernard R. Chaitman,I. Holme,David Kallend,Lawrence A. Leiter,Eran Leitersdorf,John J.V. McMurray,Hardi Mundl,Stephen J. Nicholls,Prediman K. Shah,Jean-Claude Tardif,R. Scott Wright,R. Scott Wright +17 more
TL;DR: In patients who had had a recent acute coronary syndrome, dalcetrapib increased HDL cholesterol levels but did not reduce the risk of recurrent cardiovascular events.
Journal ArticleDOI
Cholesterol Lowering With Simvastatin Improves Prognosis of Diabetic Patients With Coronary Heart Disease: A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)
Pyŏrälä K,Terje R. Pedersen,John Kjekshus,Ole Faergeman,Anders G. Olsson,Gudmundur Thorgeirsson +5 more
TL;DR: It is suggested that cholesterol lowering with simvastatin improves the prognosis of diabetic patients with CHD and the absolute clinical benefit achieved by cholesterol lowering may be greater in diabetic than in nondiabetic patients withCHD because diabetic patients have a higher absolute risk of recurrent CHD events and other atherosclerotic events.
Journal ArticleDOI
High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial.
Terje R. Pedersen,Ole Faergeman,John J.P. Kastelein,Anders G. Olsson,Matti J. Tikkanen,Ingar Holme,Mogens Lytken Larsen,Fredrik S. Bendiksen,Christina Lindahl,Michael Szarek,John Tsai +10 more
TL;DR: In this article, the authors showed that intensive lowering of LDL-C did not result in a significant reduction in the primary outcome of major coronary events, but did reduce the risk of other composite secondary end points and nonfatal acute MI.